Login / Signup

Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy.

Candice JamoisEkaterina GibianskyLeonid GibianskyVincent BuchheitDenis SahinGuillaume CartronRobert MarcusWolfgang HiddemannJohn F SeymourJonathan C StreffordChantal E HargreavesGeorgina Meneses-LorenteNicolas FreyGünter Fingerle-Rowson
Published in: British journal of clinical pharmacology (2019)
It remains unclear whether for G-CHOP/CVP patients lower G exposure is a consequence of adverse disease biology and/or resistance to chemotherapy backbone (higher clearance in nonresponder patients, as demonstrated for rituximab) rather than being the cause of poorer clinical outcome. A study with >1 dose level of G could help resolve this uncertainty.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • diffuse large b cell lymphoma
  • prognostic factors
  • emergency department
  • patient reported outcomes
  • patient reported
  • rectal cancer